Study: Cervical cancer deaths drop sharply among vaccinated women

Why it matters locally: The findings underscore the public health benefits of human papillomavirus (HPV) vaccination programs, which are implemented across California schools and healthcare systems to reduce cervical cancer rates among young women.

---

A recent study documents a significant decline in cervical cancer deaths among young women following the introduction of HPV vaccination programs in schools over the past 15 years. Researchers found that hundreds of lives have been saved since health authorities began offering the human papillomavirus vaccine to school-age girls in 2008. The study examined mortality rates among vaccinated populations compared to unvaccinated cohorts. Cervical cancer develops from infections with certain strains of HPV, a virus transmitted through sexual contact. The vaccine targets the virus before infection occurs, preventing the precancerous changes that can lead to malignancy. The findings contribute to existing evidence on vaccine effectiveness. Earlier research has shown that HPV vaccination reduces the incidence of precancerous cervical lesions and genital warts in vaccinated populations. The new study extends that data by measuring mortality outcomes in the years following widespread vaccination campaigns. Healthcare officials in countries with established vaccination programs have tracked infection and disease rates as vaccinated cohorts aged into adulthood. The timing of the 2008 rollout means the first vaccinated groups are now in their late twenties and early thirties, an age range where cervical cancer can begin to appear. The vaccine protects against multiple HPV strains. Public health agencies have expanded recommendations over time, initially targeting girls and later recommending vaccination for boys and young men as well. Screening for cervical cancer through Pap tests and HPV testing remains standard clinical practice. Health officials typically recommend that screening continue for vaccinated women, as no vaccine provides complete protection against all cancer-causing HPV strains. The study adds to a growing body of research on long-term vaccine outcomes. Researchers continue to monitor vaccinated populations to assess durability of protection and identify any potential long-term effects.